A certain pharmaceutical company may send their investors packing for 3 reasons

CHAM, Switzerland - Sept. 19, 2022 - PRLog -- Thanks to an interest rate-driven market turbulence and a host of regulatory and logistical obstacles for the biotech's quest to economically launch its Coronavirus vaccine candidate, Nuvaxovid.

Given the firm's problems, investors must now decide if the company is still a suitable investment. Let's look at three of the most recent reasons why stockholders might choose to bail rather than sticking it out.

First of all, NVAX's financial performance isn't meeting expectations, which is the most compelling cause for shareholders to consider selling. According to the company's quarterly statement on May 9, sales of its Nuvaxovid jab totalled just $586 million in the first quarter. Given that management is sticking to its sales projection of $4 billion to $5 billion for 2022, NVAX will have to significantly improve to avoid further disappointing investors.

Secondly, the company is still having trouble getting its vaccines into people's hands, even where the vaccine is licensed. Its dosage delivery to the Philippines and Europe were delayed earlier this year, and things don't appear to have changed much since then. Because of the delay, Philippine officials have raised the idea of cancelling or renegotiating the country's order, despite the fact that it had met its demands in the interim through other suppliers.

Lastly, working with authorities hasn't always gone as well as investors would want. Even obtaining the Food and Drug Administration (FDA) to notify the corporation when an advisory group will be reviewing their application package took longer than normal. Part of the problem appears to be that authorities are continuously asking for more information about the company's production procedures. Due to similar setbacks in the summer of last year, the biotech comapny had to repeatedly postpone preparations for its regulatory filing.

Regardless, the FDA advisory group will vote on NVAX's request for an Emergency Use Authorization (EUA) in the United States on June 7. Though the committee's vote isn't legally enforceable, the FDA usually follows it when deciding whether to approve or reject a drug, so there's a good probability of a significant price change in the wake of the advisory meeting.

Catch up-to-date press release and more at Medical Infralytix Pvt Ltd services, do visit our website at https://meditherma.com/ or contact us thru email.